"The expertise of Illuminera's cbh team left a deep impression on me. The team not only demonstrates deep insights into China’s Big Health market and consumers, but also excels in helping clients clarify business challenges and deliver tailored solutions. From market research and business modelling to financial projections, cbh enabled us to make informed decisions in a highly complex environment through systematic analysis and evaluation."
——— Jan Lu，
Strategy Planning Head，Alfasigma
With policy incentives and a rapidly expanding cross-border e-commerce ecosystem, more overseas health supplement brands are accelerating their entry into China. Alfasigma - an Italian multinational pharmaceutical company with a robust global portfolio in nutraceuticals and consumer health - aims to introduce its innovative health supplements into China, bringing more high quality choices to Chinese consumers.
Yet the key question remains: How can Alfasigma leverage its strengths to build a competitive foothold in China’s cross-border health supplements market? The brand urgently needed clarity on its strategic priorities to guide critical commercial decisions.
cbh (Consumer & Big Health), an Illuminera boutique, partnered with Alfasigma to unlock breakthrough pathways in China’s Cross-Border E-Commerce (CBEC) health supplements market. From portfolio optimization to business model innovation, cbh designed a structured market entry roadmap - helping Alfasigma make a compelling entry into China’s consumer healthcare landscape.
Navigating Core Business Priorities: Avoiding Detours in a Complex Market
For overseas entrants, China’s cross-border health supplements market resembles a labyrinth -crowded competition, a fragmented and fast-moving big health industry, diverse and evolving business models, complex supply chains and partnership ecosystems, and limited local operating experience. Beyond external challenges, the brand’s internal decisions shape its success: defining the right product strategy and business model to anchor its market entry.
Alfasigma’s wide-ranging global portfolio spans multiple countries and categories, with overlaps and blurred boundaries. Without strategic refinement, a large portfolio risks internal cannibalization in China. The brand needed to streamline its products into a clear, market fit matrix.
Meanwhile, a simple replication of global playbooks would not suffice. Agile Chinese players operate with fast iteration and adaptive tactics, which required Alfasigma to have a localized strategy aligned with China’s unique market dynamics.
Selecting an optimal CBEC model and platform is equally crucial. Entering China also demands forward looking financial projections - a disciplined breakdown of key financial indicators is essential for evaluating investments and returns. Additionally, for overseas brands navigating regulatory uncertainty, strong compliance risk assessment is critical to ensure safe and sustainable market entry.
Strategic Market Navigation: Building a Product Roadmap and Brand Strategy for China
Amid the complexity of CBEC, cbh team leveraged its dual expertise in FMCG and healthcare, paired with deep knowledge of cross-border business ecosystems, to guide Alfasigma’s strategic exploration of China’s health supplements market - laying the foundational groundwork for a successful market entry.
Using multi-dimensional analysis and real consumer data, cbh conducted a systematic assessment of more than 60 Alfasigma product lines,
through an integrated review of market potential, competition, regulatory pathways, supply chain feasibility, consumer needs, and product influence, finally identified an optimized product portfolio for China:
• 4 flagship products
• 4 high-potential products
• 8 long-tail products
This resulted in a competitive, China-specific product matrix aligned with local category dynamics.
Defining a brand strategy was another key step. Alfasigma already had an established prescription drug brand identity in China. Introducing a cross-border consumer health line raised critical strategic questions: Should a unified consumer-facing master brand be created? Or should sub-brands operate independently? Who are the direct competitors? What existing brand assets or corporate DNA can be leveraged?
Guided by these questions, cbh helped Alfasigma define its overarching brand strategy -clarifying brand positioning, competitive advantages, and building a comprehensive Brand House.
Leveraging CBEC: Decoding Business Models and Breaking Market Barriers
Three mainstream cross-border import models dominate the market: CBEC Bonded Warehouse model, CBEC Direct Mail model, and Personal Direct Mail model. After expert interviews and competitive reviews, cbh systematically evaluated the differences and advantages among these models. By aligning each product’s positioning with the most suitable import pathway, cbh offered a precise strategy blueprint for Alfasigma’s market entry decisions.
The core advantages and differences among three CBEC models
Following model selection, cbh built a structured four-step CBEC strategy framework to address Alfasigma’s core commercial questions:
Deconstructing the CBEC Model
Step 1: Where to Play
Assess platform options - Tmall Global, JD Worldwide, Douyin - and define store roles and positioning.
Step 2: How to Play
Determine the ideal business model, such as general distributor, distributor, or brand self operation.
Step 3: What to Sell
Design a strategic product portfolio map to build an integrated “platform × store type × product” matrix.
Step 4: How to Communicate
Develop a consumer engagement strategy, including social seeding on platforms such as Red.
What is Alfasigma’s true commercial potential in China? cbh constructed a detailed financial model projecting five-year ROI. This model visualized key indicators including revenue trajectory, product contribution, and marketing investment planning.
Kevin Cai, Director of cbh and the project lead, noted: "For market entry strategy projects, our mission is to help clients answer core business questions around product positioning, marketing strategy, capability building, and profit models. Success does not come from solving each question in isolation, but from identifying the overarching business framework that integrates them, while systematically evaluating the strengths and weaknesses of each model to support optimal commercial decision-making."
Beyond a single entry plan, cbh also developed multiple annual business scenarios - adjusting product priorities, platform sequences, and investment scales - to help Alfasigma evaluate potential returns and break-even points across different business models.
END
For overseas health supplement brands, entering China is a powerful lever to unlock exponential market potential. With a holistic strategic lens and multi-dimensional data capabilities, cbh is committed to building clear and comprehensive China entry strategies - from product portfolio design and brand positioning to business model selection, capability assessment, and financial forecasts - empowering brands to make precise decisions and achieve sustainable commercial growth.
For more relevant information, please send an email to marketing@illuminera.com.
